H.C. Wainwright Remains Bullish on Legend Biotech (LEGN), Cites Solid Growth Trajectory for CARVYKTI Therapy

Legend Biotech Corporation (NASDAQ:LEGN) is one of the 15 stocks set to explode in 2026.

On October 17, 2025, H.C. Wainwright analyst Mitchell Kapoor reiterated his “Buy” rating on Legend Biotech Corporation (NASDAQ:LEGN) with a $60 price target.

Discussing the company’s robust growth trajectory for its CARVYKTI therapy, he pointed toward the therapy’s rising clinical potential. Kapoor particularly emphasized the inclusion of overall survival (OS) data in the therapy’s label, which he regards as an underappreciated catalyst for long-term adoption. Furthermore, he highlighted the company’s confidence in CARVYKTI’s estimated $5 billion peak sales potential with robust YoY and sequential growth.

Previously, on October 10, 2025, the FDA approved a label update for CARVYKTI to include overall survival data from the Phase 3 CARTITUDE-4 study. With this update, confidence in CARVYKTI’s long-term durability was bolstered, as it now demonstrates a significant survival benefit for patients with relapsed, refractory multiple myeloma compared to standard care. However, the label also warned about serious immune-related side effects. It emphasized the need for careful management by physicians.

Legend Biotech Corporation (NASDAQ:LEGN) is focused on developing and commercializing innovative cell therapies for the treatment of multiple myeloma.

While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Fortune 500 Stocks to Invest in Now and 13 Best Fortune 500 Stocks to Invest in Now.

Disclosure: None.